+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Substance Abuse Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026

  • ID: 4851472
  • Report
  • March 2019
  • Region: Global
  • 217 pages
  • Transparency Market Research
1 of 2

Global Substance Abuse Treatment Market: Overview 

Substance abuse is use of psychoactive substances, including alcohol and illicit drugs. Use of psychoactive substances can lead to dependence syndrome (a combination of behavioral, cognitive, and psychological phenomenon, which forces the individual to use alcohol, nicotine, and illicit drugs). Awareness about initiatives by manufacturers and governments and rise in abuse of prescription drugs are likely to fuel the global substance abuse treatment market from 2018 to 2026.

The global substance abuse treatment market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on treatment type, distribution channel, and region. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the overview section. Additionally, the section comprises competitive matrix and company profiles along with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis by geography and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global substance abuse treatment market. 

Global Substance Abuse Treatment Market: Key Segments 

The report offers detailed segmentation of the global substance abuse treatment market. Based on treatment type, the global substance abuse treatment market has been classified into alcohol addiction treatment, nicotine addiction treatment, and drug abuse treatment.  The alcohol addiction treatment segment is likely to expand at a prominent growth rate during the forecast period, due to increasing consumption of alcohol worldwide, rising use of medicines for restriction of alcohol consumption, and relatively lower cost per prescription for these medicines. The duration of action is also an important driver of the segment. 

On the other hand, expansion of the drug abuse treatment segment is attributed to a rise in the usage of prescription drugs/illicit drugs, increase in the number of deaths from excessive use of prescription drugs, and a surge in research & development by leading pharmaceutical companies. 

In terms of distribution channel, the global substance abuse treatment market has been categorized into hospital pharmacies, retail pharmacies and drug stores, and others (online sales). Expansion of the segment can be attributed to the rise in prescription filling at hospital pharmacies, availability of certified physicians in hospital pharmacies, advice for use of the drugs from certified physicians, and authenticity of quality and price of medicines. The market has been analyzed based on price variations, technology trend, and presence of key players. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. 

Global Substance Abuse Treatment Market: Regional Outlook

In terms of region, the global substance abuse treatment market has been segmented into five major regions and the key countries in the respective regions: North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (China, India, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East (South Africa, GCC Countries and Rest of Middle East & Africa ). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions. 

Companies Mentioned in Report

The report also profiles the major players in the market in terms of various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in the global substance abuse treatment market are Alkermes, Allergan PLC, Indivior PLC, Noramco (part of SK Capital Partners), and Teva Pharmaceutical Industries Ltd. Other players include Pfizer, Inc., GlaxoSmithKline plc, Mallinckrodt plc, BioCorRx, Inc., and Glenmark Pharmaceuticals Ltd.

Note: Product cover images may vary from those shown
2 of 2
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Assumptions and Acronyms Used

2. Research Methodology

3. Executive Summary

4. Market Overview
4.1. Introduction
4.2. Key Industry Evolution/Developments
4.3. Market Dynamics
4.3.1. Drivers
4.3.1.1. Awareness about Initiatives by Manufacturers and Governments
4.3.1.2. Favorable Reimbursements for Smoking Cessation Therapy and Growth in the Number of Private Insurance Players
4.3.1.3. Surge in Disposable Income
4.3.1.4. Growing Abuse of Prescription Drugs
4.3.2. Restraints
4.3.2.1. Low Awareness about Addiction Treatment Products in Developing Countries
4.3.2.2. Legal Obligations for Addiction Treatment Products
4.3.3. Opportunities
4.3.3.1. Research and Development
4.3.3.2. Introduction of New Products
4.3.4. Trends
4.3.4.1. Rise in Mergers and Acquisitions in the Industry
4.3.4.2. Government Initiatives and Funding
4.4. Global Substance Abuse Treatment Market Forecast
4.5. Porter’s Five Forces
4.6. Pipeline Analysis
4.7. Porter’s Five Forces
4.8. Key Mergers and Acquisitions
4.9. Regulatory Scenario

5. Global Substance Abuse Treatment Market, by Treatment Type
5.1. Introduction and Definitions
5.2. Key Findings
5.3. Global Substance Abuse Treatment Market Analysis, by Treatment Type
5.4. Global Substance Abuse Treatment Market Forecast, by Treatment Type
5.4.1. Alcohol Addiction Treatment
5.4.1.1. Acamprosate;
5.4.1.2. Disulphirum;
5.4.1.3. Naltrexone;
5.4.1.4. Benzodiazepines Wound Care Devices
5.4.2. Nicotine Addiction Treatment
5.4.2.1. Total NRT therapy ;
5.4.2.2. Varenicline;
5.4.2.3. Bupropion
5.4.3. Drug Abuse Treatment
5.4.3.1. Methadone;
5.4.3.2. Buprenorphine;
5.4.3.3. Naltexone
5.5. Global Substance Abuse Treatment Market Attractiveness Analysis, by Treatment Type

6. Global Substance Abuse Treatment Market Analysis and Forecast, by Distribution Channel
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Global Substance Abuse Treatment Market Value Forecast, by Distribution Channel, 2016-2026
6.3.1. Hospital Pharmacies;
6.3.2. Retail Pharmacies and Drug Stores;
6.3.3. Others (Online Sales)
6.4. Global Substance Abuse Treatment Market Attractiveness Analysis, by Distribution Channel

7. Global Substance Abuse Treatment Market Analysis and Forecast, by Region
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Global Substance Abuse Treatment Market Value Forecast, by End-user, 2016-2026
7.3.1. North America
7.3.2. Europe
7.3.3. Asia-Pacific
7.3.4. Latin America
7.3.5. Middle East & Africa
7.4. Global Substance Abuse Treatment Market Attractiveness Analysis, by Region

8. North America Substance Abuse Treatment Market Analysis and Forecast, 2018-2026
8.1. Key Findings
8.2. North America Substance Abuse Treatment Market Overview
8.3. North America Substance Abuse Treatment Market Value Share Analysis, by Country
8.4. North America Substance Abuse Treatment Market Size and Forecast, by Country
8.4.1. U.S.
8.4.2. Canada
8.5. North America Substance Abuse Treatment Market Value Share Analysis, by Treatment Type
8.6. North America Substance Abuse Treatment Market Size and Forecast, by Treatment Type
8.6.1. Alcohol Addiction Treatment
8.6.1.1. Acamprosate;
8.6.1.2. Disulphirum;
8.6.1.3. Naltrexone;
8.6.1.4. Benzodiazepines
8.6.2. Nicotine Addiction Treatment
8.6.2.1. Total NRT therapy ;
8.6.2.2. Varenicline;
8.6.2.3. Bupropion
8.6.3. Drug Abuse Treatment
8.6.3.1. Methadone;
8.6.3.2. Buprenorphine;
8.6.3.3. Naltexone
8.7. North America Substance Abuse Treatment Market Value Share Analysis, by Distribution Channel
8.8. North America Substance Abuse Treatment Market Size and Forecast, by Distribution Channel
8.8.1. Hospital Pharmacies;
8.8.2. Retail Pharmacies and Drug Stores;
8.8.3. Others (Online Sales)
8.9. North America Substance Abuse Treatment Market Size and Forecast, by Market Attractiveness
8.9.1. By Treatment Type
8.9.2. By Distribution Channel
8.9.3. By Country

9. Europe Substance Abuse Treatment Market Analysis and Forecast, 2018-2026
9.1. Key Findings
9.2. Europe Substance Abuse Treatment Market Overview
9.3. Europe Substance Abuse Treatment Market Value Share Analysis, by Country/Sub-region
9.4. Europe Substance Abuse Treatment Market Size and Forecast, by Country/Sub-region
9.4.1. Germany
9.4.2. France
9.4.3. U.K.
9.4.4. Spain
9.4.5. Italy
9.4.6. Russia
9.4.7. Rest of Europe
9.5. Europe Substance Abuse Treatment Market Value Share Analysis, by Treatment Type
9.6. Europe Substance Abuse Treatment Market Size and Forecast, by Treatment Type
9.6.1. Alcohol Addiction Treatment
9.6.1.1. Acamprosate;
9.6.1.2. Disulphirum;
9.6.1.3. Naltrexone;
9.6.1.4. Benzodiazepines
9.6.2. Nicotine Addiction Treatment
9.6.2.1. Total NRT therapy ;
9.6.2.2. Varenicline;
9.6.2.3. Bupropion
9.6.3. Drug Abuse Treatment
9.6.3.1. Methadone;
9.6.3.2. Buprenorphine;
9.6.3.3. Naltexone
9.7. Europe Substance Abuse Treatment Market Value Share Analysis, by Distribution Channel
9.8. Europe Substance Abuse Treatment Market Size and Forecast, by Distribution Channel
9.8.1. Hospital Pharmacies;
9.8.2. Retail Pharmacies and Drug Stores;
9.8.3. Others (Online Sales)
9.9. Europe Substance Abuse Treatment Market Size and Forecast, by Market Attractiveness
9.9.1. By Treatment Type
9.9.2. By Distribution Channel
9.9.3. By Country/Sub-region

10. Asia Pacific Substance Abuse Treatment Market Analysis and Forecast, 2018-2026
10.1. Key Findings
10.2. Asia Pacific Substance Abuse Treatment Market Overview
10.3. Asia Pacific Substance Abuse Treatment Market Value Share Analysis, by Country/Sub-region
10.4. Asia Pacific Substance Abuse Treatment Market Size and Forecast, by Country/Sub-region
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. Australia & New Zealand
10.4.5. Rest of Asia Pacific
10.5. Asia Pacific Substance Abuse Treatment Market Value Share Analysis, by Treatment Type
10.6. Asia Pacific Substance Abuse Treatment Market Size and Forecast, by Treatment Type
10.6.1. Alcohol Addiction Treatment
10.6.1.1. Acamprosate;
10.6.1.2. Disulphirum;
10.6.1.3. Naltrexone;
10.6.1.4. Benzodiazepines
10.6.2. Nicotine Addiction Treatment
10.6.2.1. Total NRT therapy ;
10.6.2.2. Varenicline;
10.6.2.3. Bupropion
10.6.3. Drug Abuse Treatment
10.6.3.1. Methadone;
10.6.3.2. Buprenorphine;
10.6.3.3. Naltexone
10.7. Asia Pacific Substance Abuse Treatment Market Value Share Analysis, by Distribution Channel
10.8. Asia Pacific Substance Abuse Treatment Market Size and Forecast, by Distribution Channel
10.8.1. Hospital Pharmacies;
10.8.2. Retail Pharmacies and Drug Stores;
10.8.3. Others (Online Sales)
10.9. Asia Pacific Substance Abuse Treatment Market Size and Forecast, by Market Attractiveness
10.9.1. By Treatment Type
10.9.2. By Distribution Channel
10.9.3. By Country/Sub-region

11. Latin America Substance Abuse Treatment Market Analysis and Forecast, 2018-2026
11.1. Key Findings
11.2. Latin America Substance Abuse Treatment Market Overview
11.3. Latin America Substance Abuse Treatment Market Value Share Analysis, by Country/Sub-region
11.4. Latin America Substance Abuse Treatment Market Size and Forecast, by Country/Sub-region
11.4.1. Brazil
11.4.2. Mexico
11.4.3. Rest of Latin America
11.5. Latin America Substance Abuse Treatment Market Value Share Analysis, by Treatment Type
11.6. Latin America Substance Abuse Treatment Market Size and Forecast, by Treatment Type
11.6.1. Alcohol Addiction Treatment
11.6.1.1. Acamprosate;
11.6.1.2. Disulphirum;
11.6.1.3. Naltrexone;
11.6.1.4. Benzodiazepines
11.6.2. Nicotine Addiction Treatment
11.6.2.1. Total NRT therapy ;
11.6.2.2. Varenicline;
11.6.2.3. Bupropion
11.6.3. Drug Abuse Treatment
11.6.3.1. Methadone;
11.6.3.2. Buprenorphine;
11.6.3.3. Naltexone
11.7. Latin America Substance Abuse Treatment Market Value Share Analysis, by Distribution Channel
11.8. Latin America Substance Abuse Treatment Market Size and Forecast, by Distribution Channel
11.8.1. Hospital Pharmacies;
11.8.2. Retail Pharmacies and Drug Stores;
11.8.3. Others (Online Sales)
11.9. Latin America Substance Abuse Treatment Market Size and Forecast, by Market Attractiveness
11.9.1. By Treatment Type
11.9.2. By Distribution Channel
11.9.3. By Country/Sub-region

12. Middle East & Africa Substance Abuse Treatment Market Analysis and Forecast, 2018-2026
12.1. Key Findings
12.2. Middle East & Africa Substance Abuse Treatment Market Overview
12.3. Middle East & Africa Substance Abuse Treatment Market Value Share Analysis, by Country/Sub-region
12.4. Middle East & Africa Substance Abuse Treatment Market Size and Forecast, by Country/Sub-region
12.4.1. South Africa
12.4.2. GCC
12.4.3. Israel
12.4.4. Rest of Middle East & Africa
12.5. Middle East & Africa Substance Abuse Treatment Market Value Share Analysis, by Treatment Type
12.6. Middle East & Africa Substance Abuse Treatment Market Size and Forecast, by Treatment Type
12.6.1. Alcohol Addiction Treatment
12.6.1.1. Acamprosate;
12.6.1.2. Disulphirum;
12.6.1.3. Naltrexone;
12.6.1.4. Benzodiazepines
12.6.2. Nicotine Addiction Treatment
12.6.2.1. Total NRT therapy ;
12.6.2.2. Varenicline;
12.6.2.3. Bupropion
12.6.3. Drug Abuse Treatment
12.6.3.1. Methadone;
12.6.3.2. Buprenorphine;
12.6.3.3. Naltexone
12.7. Middle East & Africa Substance Abuse Treatment Market Value Share Analysis, by Distribution Channel
12.8. Middle East & Africa Substance Abuse Treatment Market Size and Forecast, by Distribution Channel
12.8.1. Hospital Pharmacies;
12.8.2. Retail Pharmacies and Drug Stores;
12.8.3. Others (Online Sales)
12.9. Middle East & Africa Substance Abuse Treatment Market Size and Forecast, by Market Attractiveness
12.9.1. By Treatment Type
12.9.2. By Distribution Channel
12.9.3. By Country/Sub-region

13. Competitive Landscape
13.1. Competition Metrix
13.2. Company Share
13.3. Market Footprint Analysis
13.4. Company Profiles
13.4.1. Alkermes
13.4.1.1. Company Overview (HQ, Business Segments, Employee Strength)
13.4.1.2. Financial Overview
13.4.1.3. Product Portfolio
13.4.1.4. SWOT Analysis
13.4.1.5. Strategic Overview
13.4.2. Allergan PLC,
13.4.2.1. Company Overview (HQ, Business Segments, Employee Strength)
13.4.2.2. Financial Overview
13.4.2.3. Product Portfolio
13.4.2.4. SWOT Analysis
13.4.2.5. Strategic Overview
13.4.3. Indivior PLC,
13.4.3.1. Company Overview (HQ, Business Segments, Employee Strength)
13.4.3.2. Financial Overview
13.4.3.3. Product Portfolio
13.4.3.4. SWOT Analysis
13.4.3.5. Strategic Overview
13.4.4. Noramco (part of SK Capital Partners),
13.4.4.1. Company Overview (HQ, Business Segments, Employee Strength)
13.4.4.2. Financial Overview
13.4.4.3. Product Portfolio
13.4.4.4. SWOT Analysis
13.4.4.5. Strategic Overview
13.4.5. Teva Pharmaceutical Industries Ltd,
13.4.5.1. Company Overview (HQ, Business Segments, Employee Strength)
13.4.5.2. Financial Overview
13.4.5.3. Product Portfolio
13.4.5.4. SWOT Analysis
13.4.5.5. Strategic Overview
13.4.6. Pfizer, Inc,
13.4.6.1. Company Overview (HQ, Business Segments, Employee Strength)
13.4.6.2. Financial Overview
13.4.6.3. Product Portfolio
13.4.6.4. SWOT Analysis
13.4.6.5. Strategic Overview
13.4.7. GlaxoSmithKline plc,
13.4.7.1. Company Overview (HQ, Business Segments, Employee Strength)
13.4.7.2. Financial Overview
13.4.7.3. Product Portfolio
13.4.7.4. SWOT Analysis
13.4.7.5. Strategic Overview
13.4.8. Mallinckrodt plc,
13.4.8.1. Company Overview (HQ, Business Segments, Employee Strength)
13.4.8.2. Financial Overview
13.4.8.3. Product Portfolio
13.4.8.4. SWOT Analysis
13.4.8.5. Strategic Overview
13.4.9. BioCorRx, Inc.,
13.4.9.1. Company Overview (HQ, Business Segments, Employee Strength)
13.4.9.2. Financial Overview
13.4.9.3. Product Portfolio
13.4.9.4. SWOT Analysis
13.4.9.5. Strategic Overview
13.4.10. Glenmark Pharmaceuticals Ltd
13.4.10.1. Company Overview (HQ, Business Segments, Employee Strength)
13.4.10.2. Financial Overview
13.4.10.3. Product Portfolio
13.4.10.4. SWOT Analysis
13.4.10.5. Strategic Overview
13.5. Competitive Business Strategies
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll